Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1693-1700

  Salman, Sam ^a   Griffin, Susan ^b   Kose, Kay ^b   Pitus, Nolene ^b   Winmai, Josephine ^b   Moore, Brioni ^a   Siba, Peter ^b   Ilett, Kenneth F ^a,c   Mueller, Ivo ^b   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; DRUG METABOLITE; HEMOGLOBIN; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; INFECTION PREVENTION; KIDNEY FUNCTION; LIVER FUNCTION; MALARIA; MALE; PAPUA NEW GUINEA; PRESCHOOL CHILD; PRIORITY JOURNAL; REPEATED DRUG DOSE;

ANTIMALARIALS; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; PYRIMETHAMINE; SULFADOXINE;

EID: 79953211101     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01075-10     Document Type: Article

References (41)

1. Alcorn, J., and P. J. McNamara. 2002. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin. Pharmacokinet. 41:959-998.
2. Allegaert, K., J. de Hoon, R. Verbesselt, G. Naulaers, and I. Murat. 2007. Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatr. Anaesth. 17:1028-1034.
3. Allen, S. J., A. Raiko, A. O'Donnell, N. D. Alexander, and J. B. Clegg. 1998. Causes of preterm delivery and intrauterine growth retardation in a malaria endemic region of Papua New Guinea. Arch. Dis. Child. Fetal Neonatal Ed. 79:F135-F140.
4. Anand, K. J., et al. 2008. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br. J. Anaesth. 101:680-689.
5. Andersen, T. B., A. Eskild-Jensen, J. Frokiaer, and J. Brochner-Mortensen. 2009. Measuring glomerular filtration rate in children; can cystatin C replace established methods? A review. Pediatr. Nephrol. 24:929-941.
6. Anderson, B. J., K. Allegaert, J. N. Van den Anker, V. Cossey, and N. H. Holford. 2007. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol. 63:75-84.
7. Anderson, B. J., and N. H. Holford. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332.
8. Anderson, B. J., and N. H. Holford. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24:25-36.
9. Aponte, J. J., et al. 2009. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374:1533-1542.
10. Baird, J. K. 2008. Real-world therapies and the problem of vivax malaria. N. Engl. J. Med. 359:2601-2603.
11. Barnes, K. I., et al. 2006. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80:582-596.
12. Bjorkman, S. 2006. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin. Pharmacokinet. 45:1-11. (Pubitemid 43145012)
13. Bokenkamp, A., et al. 1998. Cystatin C - a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 101:875-881. (Pubitemid 28204840)
14. Bouvet, Y., et al. 2006. GFR is better estimated by considering both serum cystatin C and creatinine levels. Pediatr. Nephrol. 21:1299-1306.
15. Brair, M. E., B. J. Brabin, P. Milligan, S. Maxwell, and C. A. Hart. 1994. Reduced transfer of tetanus antibodies with placental malaria. Lancet 343:208-209.
16. Bustos, D. G., et al. 2002. Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine- pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. Trop. Med. Int. Health 7:584-591.
17. Cairns, M., et al. 2008. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS One 3:e2227.
18. Corvaisier, S., et al. 2004. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob. Agents Chemother. 48:3794-3800.
19. Dzinjalamala, F. K., et al. 2005. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob. Agents Chemother. 49:3601-3606.
20. Filler, G., and N. Lepage. 2003. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr. Nephrol. 18:981-985. (Pubitemid 37236209)
21. Garner, P., et al. 1994. Birthweight and gestation of village deliveries in Papua New Guinea. J. Trop. Pediatr. 40:37-40.
22. Green, M. D., et al. 2007. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J. Infect. Dis. 196:1403-1408.
23. Grobusch, M. P., A. Egan, R. D. Gosling, and R. D. Newman. 2007. Intermittent preventive therapy for malaria: progress and future directions. Curr. Opin. Infect. Dis. 20:613-620.
24. Grubb, A., et al. 2005. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin. Chem. 51:1420-1431.
25. Hekster, C. A., and T. B. Vree. 1982. Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives. Antibiot. Chemother. 31:22-118.
26. Karunajeewa, H. A., et al. 2009. Pharmacokinetic properties of sulfadoxinepyrimethamine in pregnant women. Antimicrob. Agents Chemother. 53:4368-4376.
27. Kobbe, R., et al. 2007. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45:16-25.
28. Mansor, S. M., et al. 1989. Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. Br. J. Clin. Pharmacol. 27:381-386.
29. Marfurt, J., et al. 2007. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am. J. Trop. Med. Hyg. 77:947-954.
30. May, J., et al. 2008. Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar. J. 7:198.
31. McLeod, R., et al. 1992. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob. Agents Chemother. 36:1040-1048.
32. Obua, C., et al. 2008. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br. J. Clin. Pharmacol. 65:493-501.
33. Papua New Guinea Department of Health. 2005. Standard treatment of common illnesses of children in Papua New Guinea, 8th ed. Papua New Guinea Department of Health, Port Moresby, Papua New Guinea.
34. Potts, A. L., G. R. Warman, and B. J. Anderson. 2008. Dexmedetomidine disposition in children: a population analysis. Paediatr. Anaesth. 18:722-730.
35. Roche. 2005. Fansidar product information. Roche Products Pty. Ltd., Dee Why, Australia.
36. Schwartz, G. J., L. P. Brion, and A. Spitzer. 1987. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr. Clin. N. Am. 34:571-590.
37. Trenque, T., et al. 2004. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br. J. Clin. Pharmacol. 57:735-741.
38. Weidekamm, E., H. Plozza-Nottebrock, I. Forgo, and U. C. Dubach. 1982. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull. World Health Organ. 60:115-122.
39. Whelpton, R., G. Watkins, and S. H. Curry. 1981. Bratton-Marshall and liquid-chromatographic methods compared for determination of sulfamethazine acetylator status. Clin. Chem. 27:1911-1914.
40. Winstanley, P. A., et al. 1992. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br. J. Clin. Pharmacol. 33:143-148.
41. Zappitelli, M., et al. 2006. Derivation and validation of cystatin C-based prediction equations for GFR in children. Am. J. Kidney Dis. 48:221-230.